Medtronic rises after FDA approves new heart lead

Medtronic

23/03/2026 13:22

** Shares of medical device maker Medtronic MDT.N rise 2% to $87.79 premarket

** Co says its defibrillation lead, OmniaSecure, approved by the U.S. FDA

** A defibrillation lead is a wire that delivers shocks to the heart to correct arrhythmias or irregular heart rhythms

** The wire connects the heart to a device, known as a defibrillator, implanted in the body that applies an electric charge or shock to prevent sudden cardiac arrest

** Co says device is the first to be cleared for placement in the heart's left bundle branch area, helping it beat in a natural way

** Adds FDA's approval backed by global study showing 100% success in stopping abnormal rhythms with low complications

** OmniaSecure can be used in adults and children aged 12 and older and may help heart failure patients needing resynchronization therapy - MDT

** Shares down ~10% YTD vs. ~20% rise in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))